| Joshua Baker Weil, MD | |
|
401 Bicentennial Way, Santa Rosa, CA 95403-2149 | |
| (707) 571-4000 | |
| Not Available |
| Full Name | Joshua Baker Weil |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 29 Years |
| Location | 401 Bicentennial Way, Santa Rosa, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508945643 | NPI | - | NPPES |
| 00A610920 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | A61092 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kaiser Foundation Hospital-santa Rosa | Santa rosa, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Permanente Medical Group Inc | 8921910225 | 7800 |
News Archive
ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, today announced that the U.S. Patent and Trademark Office has issued a patent on methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient has a specific genotype - homozygous for the arginine 389 polymorphism in the beta-1 adrenergic receptor.
Scientists have analysed data from around the world to examine the accuracy of antibody tests for COVID-19, and have shown that the timing of testing is critical. The tests do not work accurately when administered at the wrong time.
Morphotek, Inc. announced today that it has commenced a multi-center, Phase II study evaluating the safety and efficacy of MORAb-004 when combined with gemcitabine and docetaxel in the treatment of metastatic soft tissue sarcoma.
Using Department of Defense supercomputers, Southwest Research Institute is virtually screening millions of drug compounds to search for and test possible treatment options for the novel coronavirus 2019.
› Verified 7 days ago
| Entity Name | Permanente Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073606299 PECOS PAC ID: 8921910225 Enrollment ID: O20031104000710 |
News Archive
ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, today announced that the U.S. Patent and Trademark Office has issued a patent on methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient has a specific genotype - homozygous for the arginine 389 polymorphism in the beta-1 adrenergic receptor.
Scientists have analysed data from around the world to examine the accuracy of antibody tests for COVID-19, and have shown that the timing of testing is critical. The tests do not work accurately when administered at the wrong time.
Morphotek, Inc. announced today that it has commenced a multi-center, Phase II study evaluating the safety and efficacy of MORAb-004 when combined with gemcitabine and docetaxel in the treatment of metastatic soft tissue sarcoma.
Using Department of Defense supercomputers, Southwest Research Institute is virtually screening millions of drug compounds to search for and test possible treatment options for the novel coronavirus 2019.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joshua Baker Weil, MD 1800 Harrison St Fl 7, Oakland, CA 94612-3466 Ph: (510) 625-6262 | Joshua Baker Weil, MD 401 Bicentennial Way, Santa Rosa, CA 95403-2149 Ph: (707) 571-4000 |
News Archive
ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, today announced that the U.S. Patent and Trademark Office has issued a patent on methods for determining whether to administer or prescribe bucindolol to a patient based on whether the patient has a specific genotype - homozygous for the arginine 389 polymorphism in the beta-1 adrenergic receptor.
Scientists have analysed data from around the world to examine the accuracy of antibody tests for COVID-19, and have shown that the timing of testing is critical. The tests do not work accurately when administered at the wrong time.
Morphotek, Inc. announced today that it has commenced a multi-center, Phase II study evaluating the safety and efficacy of MORAb-004 when combined with gemcitabine and docetaxel in the treatment of metastatic soft tissue sarcoma.
Using Department of Defense supercomputers, Southwest Research Institute is virtually screening millions of drug compounds to search for and test possible treatment options for the novel coronavirus 2019.
› Verified 7 days ago
Barry Smith, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: Santa Rosa Memorial Hospital, 1165 Montgomery Drive, Santa Rosa, CA 95405 Phone: 707-522-1573 | |
Dr. Ridgely Oliver Muller, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1165 Montgomery Dr, Santa Rosa, CA 95405 Phone: 707-525-5207 Fax: 626-397-5643 | |
James John Mc Keith, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1165 Montgomery Dr, Santa Rosa Memorial Hospital, Santa Rosa, CA 95405 Phone: 707-525-5207 | |
Christina Marie Goodwin, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1165 Montgomery Dr, M/s 1w04, Santa Rosa, CA 95405 Phone: 707-547-5471 Fax: 707-525-5280 | |
Daniel T Matulich, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1165 Montgomery Dr, Santa Rosa Memorial Hospital, Santa Rosa, CA 95405 Phone: 707-552-1573 | |
Yizza Narvaez, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 401 Bicentennial Way, Santa Rosa, CA 95403 Phone: 707-684-1538 | |
S. Mitchell Savitsky, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 401 Bicentennial Way, Santa Rosa, CA 95403 Phone: 707-571-4000 |